Project Grant R01HL179312
Award Date 8/1/25
Completion Date 5/31/30
Dollars Obligated $807K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
- This federal Project Grant award of $644,997.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to identify proteomic biomarkers that can predict the progression of idiopathic pulmonary fibrosis (IPF), a severe and often fatal lung disease. The research aims to develop non-invasive assessments that can identify individuals at higher risk of developing IPF and those with more progressive forms of the disease, enabling earlier...
- This federal Project Grant award of $718,002 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to validate and expand on the discovery of unique inflammatory and hypoinflammatory endotypes within idiopathic pulmonary fibrosis (IPF) lung tissue and microenvironment. The research, conducted by the University of Kansas Medical Center Research Institute, Inc. (KUMCRI), will perform proteomic analysis on IPF bronchoalveolar lavage fluid and lung...
- This federal Project Grant award of $722,584 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of the desmosome-keratin intermediate filament network in lung epithelial injury, repair, and regeneration. The research aims to explore how dysfunction or loss of this network may contribute to idiopathic pulmonary fibrosis (IPF). The award was made to Tulane University, a private research institution with expertise in...
- This federal Project Grant award of $461,146.00, provided by the National Institute on Aging (part of the U.S. Department of Health and Human Services) under the Aging Research program (CFDA 93.866), supports research at Yale University aimed at investigating the role of fibroblast growth factor receptor (FGFR) signaling in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The key objectives are to (1) conduct in-vitro studies of FGFR isoform-specific signaling in primary lung cells and...
- This $386,756 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a research project to develop an exosomic signature for rapidly progressive idiopathic pulmonary fibrosis (IPF). The principal investigator, Dr. Christina Eckhardt, will leverage existing IPF patient cohorts and data to identify extracellular vesicle-associated microRNAs that can quantify and predict the risk of accelerated IPF...
- This federal Project Grant award of $248,999.00 was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Virginia Commonwealth University (VCU) to support research on the role of the mechanoreceptor Piezo2 in regulating cellular metabolism and driving the progression of idiopathic pulmonary fibrosis (IPF). The project aims to characterize how Piezo2 mediates metabolic adaptations in lung fibroblasts in response to increased matrix...
- This R01 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $596,179 over a 5-year period beginning on January 1, 2025 to conduct research on the role of macropinocytosis, a cellular process, in the development of pulmonary fibrosis. The research aims to determine whether inhibiting macropinocytosis can attenuate fibrosis in animal models and cell culture systems, as well as elucidate the molecular mechanisms by...
- This Project Grant award of $786,147.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of hypoxia-induced lactate generation and shuttling in promoting pro-fibrotic phenotypes in lung fibroblasts. The research aims to elucidate the mechanistic links between hypoxia, aberrant lactate metabolism, and the pathobiology of progressive fibrotic lung disease, such as idiopathic pulmonary fibrosis (IPF). The...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,061,189 to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The key objectives are to study epithelial cell regulation of fibrosis and its interaction with myeloid cells, uncover mechanisms for impaired innate immunity against gram-positive infections in fibrosis, test delivery of targeted therapeutics...
- The Project Grant award titled "Alveolar Epithelial Stress Signaling in Lung Fibrosis" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $683,564.00 over the period of Jul 1, 2025 to Mar 31, 2030. The award supports comprehensive research focused on understanding the role of aberrant alveolar epithelial cells in the pathogenesis of pulmonary fibrosis, a devastating and progressive lung disease. The research aims to investigate...